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This article is adapted from a speech Dr. de Groot delivered in June 2020 as
President, Health Care & Education, of the American Diabetes Association at the
Association’s 80th Scientific Sessions, which was held online as a result of
coronavirus disease 2019. Dr. de Groot is an Associate Professor of Medicine
in the Division of Endocrinology, Diabetes and Metabolism at Indiana University
(IU) School of Medicine. She serves as the Acting Director of the IU Diabetes
Translational Research Center. Dr. de Groot is the 2020 recipient of the Rachmiel
Levine Medal for Leadership from the American Diabetes Association.
In theyear2020,wemarked the50thanniversaryof thefieldofbehavioral science in
diabetes in the modern era. Over this relatively short period of time, this field has
charted the psychosocial landscape of prediabetes and diabetes by establishing the
prevalence and impact of emotional and behavioral aspects of diabetes. Inter-
ventions to address these conditions have been developed that span the T2 to T4
translational research spectrum ranging from the intrapsychic to population-based
interventions. Policies ranging from standards of care to Medicare benefits have
been implemented. A review of research in the area of diabetes and depression is
provided as an example of innovations in this field. Behavior is the foundation of all
interventionswemake indiabetes andprediabetes. As amature science, it is critical
to stemming the tide of diabetes and its outcomes. To make additional strides, we
must rebalance our focus and augment funding for behavioral interventions for
individuals, communities, and health care systems in conjunction with other forms
of treatment.
When my presidential term began in January 2020, I never imagined that the 80th
Scientific Sessions of the American Diabetes Association (ADA), where I would deliver
my presidential address, would be our first ever virtual Scientific Sessions or that I
wouldbe seeingall ofmypatients inmyclinical practiceonvirtual platforms. Thanks to
coronavirus disease 2019 (COVID-19), wehave allmade tremendous pivots in theway
we do everythingdclinical care, research, and even the way we interact at pro-
fessional conferences like our Scientific Sessions.
This year, we mark 50 years of behavioral science in diabetes in the modern era. I
would like to sharewith you a portion ofmy experiencewith diabetes and a sample of
the many milestones of the remarkable journey of this field.
Growing up in my family, there was never a time when I did not know the word
“diabetes.” The disease has played a formative role in the lives of three generations of
my family, affecting my maternal grandmother, my mother, my brother, and me. My
mother, Patricia, and her older sister Julianne were born in Sacramento, California,
before the U.S. entered into World War II. My grandfather worked for the State of
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California printing office, and my grand-
mother was a homemaker. My mother
and Julianne enjoyed a happy early child-
hood. In 1943, at the age of 10 years,
Julianne became unexpectedly ill, slip-
ping into a diabetic ketoacidosis coma
before the family doctor could be called.
More than 50 years later, my grand-
mother could still describe the sugar
crystals that formed inside the toilet
bowl from Julianne’s polyuria. Although
Julianne was hospitalized and treated
with high doses of insulin, she tragically
died of cerebral and pulmonary edema
hours after my grandparents left her
hospital bedside. Julianne died of un-
diagnosed type 1 diabetes.
The legacy of Julianne’s death left an
indelible mark on three generations in
my family. For my grandmother, there
was lifelong complicated bereavement,
severe depression, and unrelenting self-
blame for “failing” to recognize thesymp-
toms of diabetes that were not widely
knownat that time. Formymother, bearing
witness to the lossofheronly sibling lefther
with theburdenof survivorship, growingup
in the impossible shadow of what her sister
“would have become” at each of her own
developmental milestones and many life
accomplishments.
Forme, the legacyof this lossbecamea
mandate of conscience: to devote my
energy to improving life with diabetes
and to lessen the physical and emotional
pain associated with type 1 and type 2
diabetes. For my brother Michael and
me, it also represented a genetic risk
factor. For Michael, that risk factor even-
tually tipped the scales for the develop-
mentofhis type2diabetes.Henowwalks
the all-too-familiar journey of coping
with the daily demands of this disease.
Fortunately, he does not walk alone. My
sister-in-lawKristin, nephewNathan, and
niece Josephineare there to support him.
As a family, they have had to learn how to
avoid becoming the “diabetes police” by
asking himhow they can provide support
that is truly helpful to him. As his sister,
that applies to me, too. The journey of
caring for diabetes has also been shared
by my partner Brad and his sister Freya.
Freya was diagnosed with type 1 diabe-
tes at the age of 13 years and bravely
managed her diabetes and its complica-
tions for nearly 55 years.
I share this personal story not simply
because it is a story about people I love
but because it mirrors the psychosocial
landscape of diabetes that affects 34.2
million adults, children, and families in
the U.S. (1). Themes of loss associated
with the course of diabetes, adjustment
to diagnosis, the enduring and changing
impact of diabetes on the lives of pa-
tients, parents, and siblings, the critical
role of social support, and experiences of
depression and diabetes distress apply,
in some measure, to everyone affected
by diabetes. These themes are also cen-
tral to the modern history of behavioral
science in diabetes.
A BRIEF HISTORY OF 50 YEARS OF
BEHAVIORALSCIENCEINDIABETES
The terms we use to describe this aspect
of science in diabetes have evolved over
time, just as our understanding of the
complexities of living with diabetes has
grown. The first term that applies to this
field is “behavioral science.”Whitley and
Kite (2) have defined it as being “com-
posed of three interrelated aspects: re-
search that generates knowledge, theory
that organizes knowledge, and applica-
tion that puts knowledge to use” (2).
While still applicable, this term has since
broadened to incorporate a continuum
of research that spans from understand-
ing mechanisms of action in biopsycho-
social phenomena (phase T2 translational
research) to the evaluation of interven-
tions in their target environments through
effectiveness studies (T3) to population
health and implementation science (T4)
(Fig. 1) (3).
As our definitions have grown, so too
has the range of expertise that has been
brought to bear on these intricate prob-
lems. The T2–T4 diabetes translational
workforce is diverse, spanning many dis-
ciplines, scientific traditions, and areas of
expertise, including social scientists, psy-
chologists, nurses,dietitians,pharmacists,
epidemiologists, physicians, social work-
ers, occupational and physical therapists,
and others. In short, this group includes
everyone who is interested in how our
patients think and feel and what they do.
Our methods are equally diverse. We
usemixedmethodologies thatallowus to
hear thevoicesofpeoplewithdiabetesand,
from these voices, measure constructs that
capture many of the facets of the lived
experience of this set of diseases.
When I first began working in diabetes
in 1991, with Alan Jacobson at the Joslin
Diabetes Center, one of the first articles
I read was “The Myth of the Diabetic
Personality,” written by John Turtle and
Stewart Dunn and published in Diabetes
Care in 1981 (4). This article called into
question the pervasive clinical attribu-
tions, dating back to Menninger in 1935
(5), that people with diabetes were im-
bued with a “diabetic personality,” de-
fined as being difficult, uncooperative,
and demanding. What had supported
this impression? Patients with diabetes
asked questions of their health care pro-
viders, they did not settle for simple
answers, and they frequently needed
more time than the typical clinical en-
counter allowed. They also struggled
with recommendations for diabetes self-
management and frequently fell short of
clinical expectations for self-care. Dunn
and Turtle (4) critically evaluated the
evidence for these clinical attributions
using early meta-analytic methodology
and advocated for the empirical evalu-
ation of the many psychosocial facets
of the lived experience of diabetes.
They called for methodologically rig-
orous behavioral science that made
careful comparisons of psychological
experiences of people with and with-
out diabetes.
This year, we mark 50 years of dis-
covery, measurement, and innovation in
behavioral science in the modern era. In
this relatively short time, three gener-
ations (and growing) of behavioral scien-
tists have developed and used rigorous
qualitativeandquantitative researchmeth-
odologies to characterize the psychosocial
and emotional landscapes of type 1 and
type 2 diabetes. The progression of this
science has been systematic. We began
with phenomenology, using qualitative
data to listen closely to these experien-
ces, and then we developed measures that
accuratelyandreliablyaccess theconstructs
of theseexperiences. From there,webegan
to link these constructs to others, searching
for physiologic, environmental, and psy-
chological correlates and potentially the
causes of these experiences.
With measurement comes the devel-
opment of interventions using study
designs to rigorously test the interven-
tion in its most pristine form. Once
established, we adapt these interven-
tions tomultiple populations, conditions,
and settings with the ultimate goal of
bringing useful tools and approaches to
improve the lives of everyone affectedby
diabetes. With these tools and data to
support their efficacy and effectiveness
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in hand, we have advanced to the level of
policy, helping to shape the ADA’s Stand-
ards ofMedical Care in Diabetes. In 2016,
I was privileged to work with Deborah
Young-Hyman, Mark Peyrot, Felicia Hill-
Briggs, Korey Hood, and Jeff Gonzalez in
writing the landmark ADA position state-
ment titled “Psychosocial Care for People
With Diabetes” (6), which summarized
and drew upon the findings of;46 years
of psychosocial data to develop stand-
ards of care in this area.
As illustrated in Fig. 2, we know that
the psychosocial landscape of diabetes
is a dynamic interplay of the character-
istics of individuals and progression of
disease across the life course (6). Evi-
dence has taught us that there is a
continuum of experiences that range
from adaptive responses to living with
diabetes to experiences we would con-
sider clinically impactful or constituting
functional impairment. All providers
have a role to play in screening, eval-
uating, and supporting adaptive emo-
tional and behavioral responses to the
ongoing course of diabetes. When im-
pairment or interference in diabetes
self-management is evident, referral
to behavioral health providers for eval-
uation and treatment is indicated; these
professionals can work interactively with
patients, families, and other members of
the health care team to address these
conditions (7).




























Figure 1—Continuum of translational research. Adapted from Sussman et al. (3).
Figure 2—Continuum of psychosocial issues and behavioral health disorders in people with diabetes. Reprinted with permission from Young-Hyman
et al. (6). *With depressed mood, anxiety, or emotion and conduct disturbance. **Personality traits, coping style, maladaptive health behaviors, or
stress-related physiological response. ***Examples include changing schools, moving, job/occupational changes, marriage or divorce, or experiencing
loss.
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In the past 50 years, we have charac-
terized the nature and impact of depres-
sion, diabetes distress, anxiety, fear of
hypoglycemia, challenges to adherence,
and the crucial role of social support in
managing type 1 or type 2 diabetes.
Today, the ADA Standards of Care in-
corporate evaluation and treatment
recommendations for the variety of psy-
chosocial conditions that come with liv-
ing with these diseases (7).
DIABETES AND DEPRESSION: AN
EXEMPLAR OF THE PROGRESSION
OF BEHAVIORAL SCIENCE IN
DIABETES
Early research indiabetes anddepression
consisted of case studies and secondary
data collected in clinical trials using de-
pression screening measures (Fig. 3)
(8,9). Initial articles reporting depres-
sion outcomes for people with diabetes
were not studies focused on this topic.
However, a pattern across these studies
began to emerge demonstrating that
people with diabetes had elevated rates
of depressive symptoms. We now know
that elevated depressive symptoms af-
fect one in four adults with type 1 or
type 2 diabetes, and clinical depression
affects one in eight peoplewith diabetes
(9).
The meta-analyses I performed with
Pat Lustman, Ray Clouse, RyanAnderson,
and other colleagues (9,10) helped to
establish these rates, which have been
borne out across multiple subsequent
studies (11,12). Work by Jacobson et al.
(13–15) and Kovacs et al. (16,17) docu-
mented elevated rates and correlates of
depression in children with type 1 di-
abetes, as well as resilience among chil-
dren and parents in coping with type 1
diabetes. Additional work documented
the validity of depression screeningmea-
sures in people with diabetes (18), the
impacts of depression on quality of life in
adultswith type 1 or type 2 diabetes (19),
and the relationship between depressive
symptoms and diabetes complications
(10,20).
Another critical area has been to un-
derstand the onset and course of de-
pression. Landmark work by Kawakami
et al. (21), Eaton et al. (22), and Golden
et al. (23,24) established a bidirectional
relationship between diabetes and de-
pression. These studies demonstrated
that a lifetime history of depression in-
creases the risk for type 2 diabetes by
38% (23), in addition to the presence of
diabetes increasing the risk of subse-
quent depression.
My own work has investigated the
duration of major depressive episodes
in adults with type 2 diabetes. My col-
leagues and I observed the duration of
major depressive episodes to be 23
months compared with 18–22 weeks in
adults in the general population (25).We
have also confirmed that comorbid de-
pression with diabetes is tenacious and
chronic, showing that a single episode of
depression increases the risk of developing
subsequent episodes with the time be-
tween subsequent episodes becoming
shorter (25).
Early intervention trials for the treat-
ment of depression in diabetes focused
on the viability of antidepressant med-
ications in adults with diabetes (26–32).
Lustman et al. (26) established that nor-
triptyline, a tricyclic antidepressant, is
an effective treatment for depression
with mild hyperglycemic effects. With
the emergence of selective serotonin
reuptake inhibitor (SSRI) antidepressants
in the 1990s, clinical trials conducted by
Lustman et al. and other research groups
(27–32)established that SSRIs showcom-
parable treatment effects to placebo
with either euglycemic or slightly hypo-
glycemic effects.
Behavioral intervention trials for de-
pression have expanded the tools and
modes of treatment that are effective
for people with diabetes. A 1998 ran-
domized controlled trial of cognitive
behavioral therapy (CBT) by Lustman
et al. (33) established that CBT was
superior to diabetes education for de-
pression amelioration.
Figure 3—Timeline of scientific advances in diabetes and depression research.
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Innovative work by Katon et al. (34,35)
at the University of Washington created
the concept of collaborative care in the
primary care setting, using a stepped-
care approach for the identification
and case management of diabetes and
depression involving problem-solving
therapy delivered by nurse case manag-
ers. Subsequent trials have tested the
effectiveness of multiple delivery modal-
ities to treat depression by expanding
treatment sites beyond the walls of
health care systems. These have included
telephone-based CBT in combination
with recommendations for regular walk-
ing, comparisons of CBT to SSRIs, and
web-based CBT delivery (36–39).
My work has focused on leveraging
resources for the treatment of depres-
sion and diabetes in partnership with
community exercise and behavioral health
providers. In the ProgramACTIVE II study
(40–42), a multistate randomized clinical
trial, my team and I tested the compar-
ative effectiveness of individual CBT,
community-based exercise, and the con-
current delivery of these interventions
against usual care. We found that both
CBT and exercise were effective in the
treatment of depression and improving
psychosocial outcomes posttreatment.
The combination of CBT and community-
based exercise over a 12-week period
also yielded significant A1C improve-
ments in the majority subsample with
a baseline A1C .7% (42).
In the relatively short period of ;50
years, our scientific knowledge of de-
pression in diabetes has advanced from
clinical impressions to the development
of large-scale interventions that are in-
creasingly tailored for effective delivery
across populations and settings. Depres-
sion is one of many psychosocial con-
ditions affecting people with diabetes.
This same progression has unfolded for
many other conditions.
THE FUTURE OF BEHAVIORAL
SCIENCE
In the ADA’s 2016 position statement on
psychosocial care (6), our writing team
was intentional in creating guidelines
thatwereprescriptive, basedonexisting
evidence, and aspirational for the fu-
ture. We posited that a key next step in
the development of behavioral science
in diabetes would be integrated care, an
approach that synergistically leverages
the expertise of multiple health care
providers who treat and care for people
with diabetes. Integrated care places the
patient-provider relationship at the center
of care,which is themilieu for assessment,
medical decision-making, recommenda-
tions, and treatment implementation
(Fig. 4) (43).
Aswehavemoved through theCOVID-
19 pandemic and advanced the large-
scale use of telehealth in recent months,
we have all taken an unanticipated leap
forward in innovations for the delivery of
care. Iwould submit toyou that, although
our modality of connecting safely with
patients has changed, the strength of our
relationships with our patients, and with
each other in the health care setting, is
more fundamental than ever.
As the recently published seven-
organization joint consensus report on di-
abetes self-management education and
support (DSMES) (43) rightly notes, the
patient-provider relationship should be
leveraged at key points in the course of
this disease, including at diagnosis, an-
nually, when complications develop or
become exacerbated, and at times of life
transition.
Another major area of needed work
in the behavioral science of diabetes is
the early identification of social deter-
minants of health for diabetes preven-
tion and diabetes treatment, paired with
interventions that create an equitable
playing field for preventing and thriving
with diabetes (44). A crucial component
of this work will involve eliminating the
many forms of stigma that surround di-
abetes. The 2017 ADA/American Associ-
ationofDiabetesEducators jointpublication
on the use of language in diabetes care
and education (45) provided a landmark
template for us all to follow to set the
words and tone in our communication
with our patients and, by so doing, re-
duce the cognitive traps that hinder
successful self-care.
Another area of emphasis in the next
50 years of behavioral science in diabetes
must be the continued development of
a strong and vibrant workforce of re-
searchers and clinicians. Here, we can
borrow lessons from our bench science
colleagues. Today, in T2–T4 diabetes
translational research, we have an evolv-
ing set of largely ad hoc individual train-
ing programs across multiple institutions
and fields. A systematic funding program
is needed to provide the next generation
of behavioral scientists with the training
opportunities needed to integrate knowl-
edge across disciplines and clinical care
environments and to support settings in
which they canuse their talents and training.
THE ADA’S EFFORTS TO ADVANCE
BEHAVIORAL SCIENCE
The ADA continues to advance program-
ming and policy that affect all people at
risk for andwith diabetes.With regard to
addressing health disparities and reduc-
ing stigma, the Association has joined
theWorldCongressWeight StigmaState-
ment (46), the first international con-
sensus statement to call for the ban of
overweight and obesity stigma in all
aspects of our societies. I was proud to
represent ADA with 100 other organiza-
tions in the creation of this landmark
statement. In July 2020, theADA launched
the #HealthEquityNow initiative to create
partnerships across community sectors to
advance research, advocacy, and accessi-
ble interventions and thereby to break
down the pillars of health disparities in
diabetes. This initiative includes the cre-
ationof aHealth EquityBill of Rights for all
people with diabetes (47).
The ADA has been leading efforts to
understand and overcome challenges
to treatment advancement through its
Overcoming Therapeutic Inertia initia-
tive. Hundreds of person-hours have
been dedicated by ADA’s professional
volunteers, staff, and industry and com-
munity partners to characterize and tar-
get this pervasive phenomenon that
poses key barriers to the timely advance-
ment of all aspects of clinical care for
diabetes. A white paper (48) recently
published in Clinical Diabetes de-
scribes this effort and sets out the
activities planned for and goals of this
3-year project.
Earlier this year, the ADA, in concert
with six sister organizations, released the
aforementioned 2020 consensus report
on DSMES for people with type 2 di-
abetes (43). The adoption by all signatory
organizations of the recommendations
included in this reportmoveus all toward
greater integration of care.
Programmatically, ADA continues to
lead access to diabetes prevention and
care through the Diabetes Prevention
Program, its Know Diabetes by Heart
collaboration with the American Heart
Association, and its Focus on Diabetes
eye health initiative with partner organ-
izations in the eye care arena.
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I am proud to say that ADA has also
collaborated with the American Psycho-
logical Association to create a Mental
Health Provider Training Program de-
signed to empower community mental
health providers to understand and ad-
dress the psychosocial landscape for
children, families, and adults with dia-
betes. To date, this program has trained
more than 450 psychologists, social
workers, and allied mental health pro-
viders nationally. Graduates from this
training program are entered into the
ADA’s National Mental Health Provider
Directory, a searchable database for
referrals by state.
ADVOCACY
During this COVID-19 pandemic, ADA
worked effectively with the U.S. Centers
for Medicare & Medicaid Services (CMS)
to advocate for the temporary approval
of the use of continuous glucose mon-
itoring (CGM) equipment during inpa-
tient hospitalizations. Advocacy efforts
are ongoing to reduce the administrative
and behavioral barriers to qualifying for
CGM use. The ADA has exerted its voice
to advocate for the expansion of CMS
reimbursement for DSMES and medical
Figure 4—Person-centered care at the center of DSMES services. Reprinted with permission from Powers et al. (43).
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nutrition therapy services and to reduce
patient and provider barriers to making
use of these essential services. The As-
sociation also continues to advocate for
the advancement of bipartisan legisla-
tion to control the cost of insulin.
NEXT STEPS TOWARD THE NEXT
GOLDEN AGE OF BEHAVIORAL
RESEARCH IN DIABETES
Recognizing that behavior is fundamen-
tal to everything we do in diabetes. we
must embrace the reality that behavioral
science is an equal partner to both
medical innovationand interventions that
we test, create, and implement. Fifty
years ago, behavioral science in diabetes
was in its infancy. Today, our science and
tools must take their place alongside
other disciplines at all levels of decision-
making fordiabetes-related funding,plan-
ning, and policy. Next, we must believe
that we can effect change in the way we
deliver care. If we build it, they will come.
With thisbelief inmind,weneedtosecure
funding for all aspects of this endeavor.
With all of theseelements inplace,wecan
achieve fully integrateddiabetes care that
leverages all of our science to prevent
diabetes before it starts and improves the
lives of all people who have diabetes.
What does this goal require of us?
First, we must practice our standards of
care. I call on all diabetes care profes-
sionals to screen and refer patients for
treatment of the psychosocial conditions
that are endemic to diabetes. Second,we
must be advocates for multidisciplinary
teams at our institutions. Sharewhat you
knowwithdecisionmakers and leadersat
all levels.Whatwehave tooffer is crucial,
not only to our patients, but also to our
health care systems. During this time
of economic flux, we must remind our
leaders of our value. Third, we must
support the funding of behavioral science
research and programs. Finally, we must
join ADA in advocating for improved ac-
cess to affordable insulin, DSMES serv-
ices, and CGM for our patientswho stand
to benefit from them.
Returning to the COVID-19 pandemic
for amoment, there aremany lessonswe
can learn from the impactful events the
world has experienced in the past year. It
is important to observe that our first
line of defense against this new biolog-
ical threat was changing behavior. Be-
havior, however variable and imperfect,
has been our first and best strategy for
keeping people safe: social distancing,
hand washing, wearing protective masks
andgloves, sheltering inplace, and taking
measure to quarantine when necessary.
These behavioral tools were and con-
tinue to be the bedrock of public health
in this time of COVID-19. Vaccines and
medications will be a welcome next wave,
buttheywillnotreplacethis initialbehavioral
strategy. Rather, they represent a different
set of therapies and behaviors that hold the
potential to improve our health outcomes.
This lesson fromCOVID-19 also applies
to diabetes. Behavior lies at the heart of
every intervention we use in diabetes,
whether it is making diet and physical
activity changes to prevent diabetes or
adding multiple medications and technolo-
gies to regulate metabolism in conjunction
with healthy living to manage diabetes.
In 2021, we will mark the 100th an-
niversary of the discovery of insulin. We
have much to celebrate with regard to
this and other remarkable innovations
that have transformed the lives of all
people with diabetes in this century. It is
insulin that would have saved Julianne’s
lifehad shebeendiagnosed in time. It has
been the journey through innovations
in insulin delivery that my sister-in-law,
Freya, walked during more than 50 years
with type 1 diabetes, as she moved from
boiling syringes when first diagnosed to
multiple daily injections.
Let us not forget that it isbehavior that
is the foundation of the success of every
innovation in medications and devices.
For patients, families, health care providers,
and insurers, it is behavior that makes it
possible for all new innovations to have an
impact. As I like to share with my patients,
medications only work if we take them.
Devices only work if we use them. The time
has come to recognize and celebrate the
foundational role that behavior plays in all
aspects of diabetes. In conjunction with
other forms of treatment, behavioral sci-
ence, as a mature discipline, is crucial to
stemming the tide of diabetes and its
negative outcomes for individuals, commu-
nities, and health care systems.
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